Immunovant, INC 8-K filings

Immunovant announced its fiscal first quarter 2026 financial results, highlighting on-track clinical development for IMVT-1402 across six indications and a robust cash balance.

Immunovant announced fourth quarter and fiscal year 2026 financial results, highlighting positive preliminary data for IMVT-1402 in rheumatoid arthritis and providing updates on its clinical pipeline.

Immunovant announced its fiscal third quarter 2025 financial results, highlighted by full enrollment in a key IMVT-1402 trial and a significant capital raise extending its cash runway.

Immunovant, Inc. successfully completed an underwritten public offering of 26.2 million shares of common stock, generating approximately $550 million in gross proceeds.

Immunovant, Inc. announced a $550 million common stock offering and provided updates on its IMVT-1402 and batoclimab clinical programs, including a delay in batoclimab TED study results.

Immunovant, Inc. announced the departure of its Chief Medical Officer, Dr. Michael Geffner, effective November 21, 2025, as part of an R&D leadership restructuring.

Immunovant announced its fiscal second quarter results, highlighting progress in IMVT-1402 development and a delay in batoclimab Phase 3 TED study readouts to early 2026.

Immunovant announced positive six-month off-treatment data for batoclimab in Graves disease, demonstrating durable response and anti-thyroid drug-free remission.

Immunovant, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of three directors and ratification of its independent auditor.

Immunovant, Inc. announced its fiscal first quarter 2025 financial results and provided updates on its clinical pipeline, including new registrational study initiations for IMVT-1402.

Immunovant, Inc. has formalized the employment agreement for its Chief Executive Officer, Eric Venker, M.D., Pharm.D., outlining his base salary, performance bonus, and significant equity awards.

Immunovant, Inc. announced its fourth quarter and fiscal year 2025 financial results, revealing increased net losses driven by significant R&D investments, while highlighting positive clinical data and an accelerated development strategy for its lead asset, IMVT-1402, across six autoimmune indications.

Immunovant appoints new CEO and CFO, expands IMVT-1402 development into Sjgrens Disease and Cutaneous Lupus Erythematosus, and realigns strategically with Roivant.

Immunovant reports positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from Period 1 of its Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating significant clinical improvements.

Immunovant announces its Q3 fiscal year 2025 results, showcasing the advancement of its lead asset IMVT-1402 and upcoming milestones for batoclimab trials.

Immunovant has filed a prospectus supplement to register the resale of up to 5,654,990 shares of its common stock by selling stockholders, following a private placement financing.

Immunovant provides a corporate overview, emphasizing the progress of IMVT-1402 and its potential in treating autoimmune diseases at the 43rd Annual J.P. Morgan Healthcare Conference.

Immunovant, a clinical-stage immunology company, has announced a $450 million private placement to fund its development pipeline and general corporate needs.

Immunovant reports significant progress with its lead asset IMVT-1402, including five cleared IND applications and plans to initiate multiple registrational trials by early 2025, while also providing financial results for the quarter ended September 30, 2024.

Immunovant reported positive Phase 2a trial results for batoclimab in Graves' Disease, showing a 76% response rate and 56% ATD-free response rate with high-dose treatment, and announced the initiation of a pivotal trial for IMVT-1402 by the end of the year.

Immunovant held its 2024 Annual Meeting of Stockholders, where directors were elected, the selection of an independent auditor was ratified, and executive compensation was approved on an advisory basis.

Immunovant announced its fiscal first quarter results, highlighting progress in clinical trials for batoclimab and IMVT-1402, and a cash position of approximately $560 million.

Immunovant is shifting its focus to IMVT-1402 as its lead asset, planning multiple registrational studies, and reported its fiscal year end results.

Immunovant announced its fiscal third quarter results, highlighting progress with its IMVT-1402 and batoclimab programs, including plans to initiate multiple registrational trials.